
Topic
Biosimilars
Follow-on biologics, reference-product erosion, payer switching, launch sequencing, and specialty-channel uptake.

Approvals· June 10, 2026 · 10 min read

Manufacturing· June 10, 2026 · 9 min read
Who supplies the world's essential medicines: 1,139 WHO-PQ products, 59% from India

Pipeline· June 8, 2026 · 11 min read
Botulinum toxin biosimilar pathway: the 351(k) race to challenge Botox
By Ran Chen#Biosimilars#FDA Approval#BLA Approval

Global· June 8, 2026 · 11 min read
South Korea MFDS biosimilar reform 2026: what US launch teams need to know
By Ran Chen#Biosimilars#Regulatory#FDA Approval

Biosimilars· June 7, 2026 · 8 min read
Langlara insulin glargine biosimilar: interchangeable Lantus, formulary, and switching

Pricing & Access· June 4, 2026 · 14 min read
TNF inhibitor access landscape: Humira, Enbrel, Remicade, Cimzia, and Simponi in 2026
By Ran Chen#Biosimilars#TNF Inhibitor#Payer Coverage

Biosimilars· June 1, 2026 · 12 min read
FDA biosimilar interchangeability without switching studies: the 2026 pathway
By Ran Chen#Biosimilars#Interchangeability#FDA Approval

Pricing & Access· May 31, 2026 · 12 min read
Biosimilar HCPCS and NDC crosswalk errors that deny claims
By Ran Chen#Biosimilars#HCPCS Coding#Payer Coverage

Biosimilars· May 31, 2026 · 12 min read
Interchangeable biosimilar substitution notices and state-law workflow
By Ran Chen#Biosimilars#Interchangeability#Payer Policy

Pricing & Access· May 31, 2026 · 9 min read